Cargando…

Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness

Pulmonary arterial hypertension (PAH) is commonly treated with pulmonary arteriolar vasodilator therapy. When a patient on PAH medication is admitted to intensive care, determining how to manage their medication during the critical illness is often complicated. There may be considerations related to...

Descripción completa

Detalles Bibliográficos
Autores principales: Muzevich, Katie M, Chohan, Hadi, Grinnan, Daniel C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331447/
https://www.ncbi.nlm.nih.gov/pubmed/25673176
http://dx.doi.org/10.1186/s13054-014-0523-z
_version_ 1782357717388623872
author Muzevich, Katie M
Chohan, Hadi
Grinnan, Daniel C
author_facet Muzevich, Katie M
Chohan, Hadi
Grinnan, Daniel C
author_sort Muzevich, Katie M
collection PubMed
description Pulmonary arterial hypertension (PAH) is commonly treated with pulmonary arteriolar vasodilator therapy. When a patient on PAH medication is admitted to intensive care, determining how to manage their medication during the critical illness is often complicated. There may be considerations related to the inability to take medication by mouth, related to acute renal failure or acute liver injury, related to altered mental status or delirium, or related to hypotension and bacteremia. Decisions of how to manage these medications can have a major impact on the patient’s clinical course. Presently, provider experience is the major tool in navigating the decisions regarding these medications. In this review, we offer our recommendations of how to manage PAH patients with critical illness who are on PAH medications. These recommendations include how to deliver medications via feeding tubes, how to dose medications in the setting of acute renal failure or acute liver failure, and how to manage medications during hypotension or when a tunneled catheter needs to be removed.
format Online
Article
Text
id pubmed-4331447
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43314472015-02-19 Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness Muzevich, Katie M Chohan, Hadi Grinnan, Daniel C Crit Care Review Pulmonary arterial hypertension (PAH) is commonly treated with pulmonary arteriolar vasodilator therapy. When a patient on PAH medication is admitted to intensive care, determining how to manage their medication during the critical illness is often complicated. There may be considerations related to the inability to take medication by mouth, related to acute renal failure or acute liver injury, related to altered mental status or delirium, or related to hypotension and bacteremia. Decisions of how to manage these medications can have a major impact on the patient’s clinical course. Presently, provider experience is the major tool in navigating the decisions regarding these medications. In this review, we offer our recommendations of how to manage PAH patients with critical illness who are on PAH medications. These recommendations include how to deliver medications via feeding tubes, how to dose medications in the setting of acute renal failure or acute liver failure, and how to manage medications during hypotension or when a tunneled catheter needs to be removed. BioMed Central 2014-10-07 2014 /pmc/articles/PMC4331447/ /pubmed/25673176 http://dx.doi.org/10.1186/s13054-014-0523-z Text en © Muzevich et al.; licensee BioMed Central Ltd. 2014 The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Muzevich, Katie M
Chohan, Hadi
Grinnan, Daniel C
Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
title Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
title_full Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
title_fullStr Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
title_full_unstemmed Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
title_short Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
title_sort management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331447/
https://www.ncbi.nlm.nih.gov/pubmed/25673176
http://dx.doi.org/10.1186/s13054-014-0523-z
work_keys_str_mv AT muzevichkatiem managementofpulmonaryvasodilatortherapyinpatientswithpulmonaryarterialhypertensionduringcriticalillness
AT chohanhadi managementofpulmonaryvasodilatortherapyinpatientswithpulmonaryarterialhypertensionduringcriticalillness
AT grinnandanielc managementofpulmonaryvasodilatortherapyinpatientswithpulmonaryarterialhypertensionduringcriticalillness